Liposomes Market To Revolve Around Home-Based Care At A CAGR Of 7%

The global Liposomes Market is all set to witness a CAGR of 7% by the year 2030. With digitized communication channels making a beeline to the healthcare vertical, the advanced clinics are into virtual consultation mode, and this scenario is expected to continue even going forward. Regulatory approvals for this type of communication are on the way. Close to 70% of the public hospitals worldwide are being asked to adopt digital means. This would be the scene with healthcare vertical in the subsequent period.

Liposomes are a novel system widely used in the field of drug delivery, gene delivery, medical imaging, and model cell membrane biology. Stealth liposome technology, DepoFoam technology, and non-PEGylated liposomal technology are gaining significant adoption in the development of liposome-based products. Growing research & development activities for the delivery of anti-fungal, anti-cancer, anti-inflammatory drugs, and therapeutic genes are boosting the demand for liposome formulations.

Liposomes have the ability to overcome the limitations of conventional therapy and provide benefits in various therapeutic applications, ranging from cancer to pain management. Encapsulation of drugs in liposomes improves the therapeutic indices of various agents.

Get Going With Sample Of Liposomes Market Report! https://www.persistencemarketresearch.com/samples/16546

According to PMR, the global liposomes market was valued at US$ 6.5 Bn in 2019, and is expected to expand at a CAGR of around 7% during the forecast period (2020-2030).

Company Profiles:

Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd
Johnson & Johnson
Dr. Reddy's Laboratories Ltd.
Sun Pharma Industries Ltd
Baxter AG
Sanofi SA
Bristol Myers Squibb
Mylan NV
GlaxoSmithKline Plc.
Creative Biolabs
Precision NanoSystems Inc.
SkyePharma Inc.
Luye Pharma Group
Encapsula NanoSciences LLC
Nanovex Biotechnologies SL
Gilead Sciences, Inc.
Avanti Polar Lipids, Inc.
Fujifilm Holdings Corporation
liposomes market

Switch over to the "Methodology" tab@ https://www.persistencemarketresearch.com/methodology/16546

Key Takeaways from Liposomes Market Study

Formulated liposomes occupied nearly 68% of the market value share in the liposomes market in 2019, owing to increasing adoption of liposome-based drug formulations. Doxorubicin and paclitaxel formulated liposomes contributed more than three-fifth of market value share in the global liposomes market.

Drug delivery applications accounted the highest market value share in the global liposomes market, on the back of rising demand for nanotechnology drug delivery. The cancer drug delivery application segment is expected to progress at the highest growth rate, due to increasing R&D activities to develop drugs for cancer.

Distributional sales hold a major share in the global liposomes market, owing to the growing demand for formulated liposomal drugs.

North America holds a prominent revenue share in the global liposomes market, as a result of rising prevalence of cancer and fungal diseases in the region. However, the liposomes market in East Asia is projected to flourish at the highest growth rate, owing to increasing pharmaceutical expenditure in the region.

The race for liposomal vaccine development to combat the ongoing COVID-19 pandemic is a catalyst for the growth of the global liposomes market.

"Rising demand for liposomal formulations and vaccines, and increasing research activities in the field of biomolecules and gene delivery, are expected to favor the growth of the liposomes market," says a PMR analyst.

Product Portfolio Expansion and Regulatory Approval - Key Strategies of Leading Liposome Manufacturers

Manufacturers in the liposomes market are focusing on product portfolio expansion and new product launches. For instance, in September 2017, Novartis received EU approval for the Rydapt® (midostaurin) drug for FLT3-mutated acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis.

Manufacturers are focusing on acquiring regulatory approval in different countries for the expansion of product sales. For instance, in October 2017, GlaxoSmithKline Plc. declared that the US Food and Drug Administration approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles in adults aged 50 years and above.

More Valuable Insights on Liposomes Market

Persistence Market Research offers a unique perspective and actionable insights on the liposomes market in its latest study, presenting historical demand assessment of 2015-2019 and projections for 2020-2030, on the basis of product (simple liposomes, formulated liposomes {doxorubicin liposomes, amphotericin B liposomes, paclitaxel liposomes, cytarabine liposomes, irinotecan liposomes, cisplatin liposomes, and others}, and vaccines), application (drug delivery {cancer, fungal infection, viral & parasite infection, and others}, gene delivery/transfection, contrast agents for medical imaging, and model cell membranes), distribution channel (retail sales {academic & research laboratories, biopharmaceutical companies, clinical research organizations, and others} and distributional sales {hospital pharmacies, retail pharmacies, mail order pharmacies, and drug stores}), across seven major regions.

Go To "Purchase Now" To Decipher The Competitive Analysis In Our Liposomes Market Report@ https://www.persistencemarketresearch.com/checkout/16546

Access Related Reports-

Dental Biomaterials Market: https://www.persistencemarketresearch.com/market-research/dental-biomaterial-market.asp

Smart Inhalers Market: https://www.persistencemarketresearch.com/market-research/smart-inhalers-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.